CHINA FEIHE (06186) recently achieved a milestone scientific advancement in the field of early infant nutrition and health. The company's R&D team, starting from the complex mechanisms by which core infant gut microbiota metabolize breast milk prebiotics (human milk oligosaccharides, HMOs), has proposed the broad application of infant nutritional compositions based on HMOs and bifidobacteria in early-life multidimensional health. The team systematically elucidated the deep mechanisms by which these two components promote infant gut health, immune system development, and brain development. The related research findings have not only gained recognition in an authoritative international SCI journal but also provide solid scientific evidence to help mothers scientifically choose formula and precisely feed their babies. Leveraging this cutting-edge research breakthrough, Feihe will continue to upgrade its products under the philosophy of being "more suitable for Chinese babies' constitutions," dedicated to safeguarding the healthy growth of millions of Chinese infants. The research results have been published in the SCI Zone 1 journal "Food & Function."
Deciphering the infant microbiome "code" and guiding infant feeding with a new theory of co-evolution. Traditional research often focused on the functions of single nutritional components, overlooking the uniqueness of the host's gut microbiota in early life and its natural synergy with breast milk components. Starting from breaking through this limitation, the Feihe team proposed the naturally occurring "nutrient-consumer" co-evolution mechanism between HMOs and bifidobacteria. This innovation not only pioneers a new direction for infant gut microbiome research, suggesting new possibilities for industry development, but also lays a solid scientific foundation for the design of precision nutrition formulas, providing parents with a new theoretical basis and professional solutions for scientific feeding.
Deep Interaction Mechanism Between HMOs and Bifidobacteria. This research transcends traditional nutritional understanding, achieving an upgrade from "meeting basic needs" to "active protection." In this mechanism, HMOs act like prebiotic "nutrients" that can be efficiently "consumed" by bifidobacteria, promoting their rapid proliferation and solidifying the dominant position of beneficial gut bacteria. This makes the baby's gut more efficient at digestion and nutrient absorption. Simultaneously, bifidobacteria metabolically produce beneficial substances like short-chain fatty acids, forming a mutually beneficial "cross-feeding" network in the gut. This helps fortify the baby's intestinal barrier, effectively protecting gastrointestinal health. Consequently, the combination of HMOs and bifidobacteria produces a synergistic effect greater than the sum of its parts, becoming the optimal combination for infant nutritional needs and meeting the high-quality nutritional demands for infant growth and development.
Furthermore, the synergistic action of HMOs and bifidobacteria not only protects infant gut health but also regulates immune balance, reducing the risk of immune-related issues like allergies. It also produces key neuroactive substances through the "gut-brain axis" metabolism, providing strong support for infant brain cognition and emotional regulation. This comprehensively aids the baby's immune and brain development, helping to build a strong immune foundation and seize the golden advantage in brain development from the earliest stages of growth.
From Lab to Bottle: Accelerating Product Upgrades with Scientific Achievements. As a research leader in China's infant formula industry, Feihe consistently drives product innovation through breast milk research. The breakthrough in the synergistic mechanism of HMOs and bifidobacteria has been rapidly translated into the core design philosophy of multiple products, building a gut microbiome and comprehensive nutrition system that closely resembles breast milk. Currently, product series such as Xingfeifan Zhuorui, Xingfeifan Zhuoyu, Qicui, and Jicui are being iteratively upgraded based on this research framework. These products generally integrate scientifically proportioned HMOs with highly active bifidobacteria. They aim to start with the gut microbiome to simultaneously support the construction of an infant's self-protection capabilities, brain development, and comfortable digestion and absorption. For example, Xingfeifan Zhuoyu has been scientifically proven to achieve "good digestion and absorption within 3 hours." Clinical data for Qicui shows that fed babies experienced approximately a 62% reduction in night wakings and a 7.7% improvement in cognitive ability. Jicui pioneered a "dual-source protection system" that internally and externally works together to strengthen the immune barrier.
For many years, Feihe has maintained high-intensity R&D. The key national "14th Five-Year Plan" project it leads has already published 21 papers and applied for 12 patents, establishing a Chinese independent intellectual property system for breast milk research. It has overcome several critical technical challenges, such as the "Fresh Extraction Active Process," and achieved 100% self-production capability for 11 key raw materials. From proposing the development of a "nutrient-consumer" co-evolution mechanism based on the infant's natural gut microbiome to translating it into the core technical language of multiple products, Feihe is using scientific research as its engine to convert R&D into tangible growth benefits for babies. In the future, Feihe will continue to deepen its efforts in the field of early-life nutrition, promoting the high-quality development of the infant nutrition industry with solutions even more tailored to the constitutions of Chinese babies.
Comments